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Abstract
Background: In this study, we pilot tested an in vitro assay of cancer killing activity (CKA) in circulating leukocytes
of 22 cancer cases and 25 healthy controls.
Methods: Using a human cervical cancer cell line, HeLa, as target cells, we compared the CKA in circulating
leukocytes, as effector cells, of cancer cases and controls. The CKA was normalized as percentages of total target
cells during selected periods of incubation time and at selected effector/target cell ratios in comparison to no-
effector-cell controls.
Results: Our results showed that CKA similar to that of our previous study of SR/CR mice was present in human
circulating leukocytes but at profoundly different levels in individuals. Overall, males have a significantly higher CKA
than females. The CKA levels in cancer cases were lower than that in healthy controls (mean ± SD: 36.97 ± 21.39
vs. 46.28 ± 27.22). Below-median CKA was significantly associated with case status (odds ratio = 4.36; 95%
Confidence Interval = 1.06, 17.88) after adjustment of gender and race.
Conclusions: In freshly isolated human leukocytes, we were able to detect an apparent CKA in a similar manner to
that of cancer-resistant SR/CR mice. The finding of CKA at lower levels in cancer patients suggests the possibility
that it may be of a consequence of genetic, physiological, or pathological conditions, pending future studies with
larger sample size.
Background
It has been hypothesized for more than 100 years that
cancer cells develop frequently in healthy individuals
due to the constant cell-damaging factors they are
exposed to from the environment [1].
Therefore, in order to remain healthy (cancer free),
t h e r em u s tb ean a t u r a l l ye x i s t i n gs y s t e mf o rc o n t i n u -
ously identifying and removing cancer cells before they
accumulate into detectable cancer lesions [2-4]. This
system, termed cancer immunosurveillance, is believed
to be critical in protecting hosts and its failure can lead
to malignancy. Further support of this system came
through the serendipitous discovery of the Spontaneous
Regression/Cancer Resistant (SR/CR) mouse [5].
Multiple human studies have investigated the relation-
ship between cancer and the immune system [6-10]. For
example in 2000, Imai et al. reported the results of an
eleven-year prospective cohort study among 3,625 Japa-
nese individuals [7]. Specifically, this study compared
the cytotoxic function of Natural Killer (NK) cells by
means of a
51Chromium release assay and an extensive
follow-up investigation of cancer incidence among the
same individuals. Their findings suggested that indivi-
duals who possessed high to medium levels of NK-
mediated natural cytotoxicity could have a reduced risk
of cancer incidence later in life. In 1984, Strayer et al.
reported studies of the possible role of cell-mediated
toxicity and familial cancer incidence [10]. Like the
methods of Imai, Strayer’s also included the use of a
51Chromium release assay to measure immunological
function. Results among 79 normal individuals in
Strayer’s studies showed that natural cell-mediated cyto-
toxicity inversely correlated with the incidence of family
members with cancer, thus, implicating their assay as a
potential marker of familial cancer risk. These findings
underscore the powerful diagnostic and prognostic tools
that can potentially arise from studies intended to
observe the immune system’s ability to fight cancer.
However, the relevance of these assays is difficult to
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sampled individual or observe this individual throughout
their lifetime for the development of cancer. A human
adaptation of the CKA assay may be preferential to pre-
vious methods, because it has been developed and vali-
dated under conditions defined by parallel observations
within an animal model of transferrable, heritable,
innate cancer resistance [11,12].
Our laboratory previously described the unique, heri-
table phenotype of cancer resistant (SR/CR) mice [5].
The SR/CR mice are capable of resisting large doses of
highly lethal cancers [5,11,13]. Our observations further
demonstrated that SR/CR cancer resistance is mediated
by a massive infiltration of predominantly innate
immune cells, which migrate directly to the site of a
tumor challenge. When observed in vitro,S R / C R
immune cells also demonstrate an innate, anti-cancer
cytotoxic function that is significantly superior to that
of the immune cells of wild type mice [5]. Remarkably,
this anti-cancer cellular activity is capable of being
transferred to non-resistant, wild-type mice, where it
has been shown to provide therapeutic resistance in a
model of established cancer [11]. The ability of SR/CR
leukocytes to mediate an enhanced innate resistance to
cancer is a trait that enabled the development of the
previously described screening assay [11]. Based on this
innate phenotype, we previously developed an in vitro
cancer cell killing assay that recapitulated the in vivo
activity of leukocytes. In this assay, cancer cells were
co-incubated with immune (effector) cells to determine
their anti-cancer activity. Through the development and
use of this assay, naïve leukocytes that demonstrated
high levels of in vitro cancer killing activity (CKA) dis-
played predictive values that were capable of distin-
guishing which mice among litters would survive a
direct challenge of cancer in vivo [11]. Given the predic-
tive value of this assay relative to SR/CR mice and cor-
responding therapeutic potential, along with the
inherently low risk involved with leukocyte collection
for in vitro screening, we set out to determine if similar
CKA could be observed from isolated human leuko-
cytes. Given that our assay was evaluated with the gui-
dance of the SR/CR mouse phenotype, we suspect that
if any CKA is to be observed in humans, its value may
eventually provide more relevant insights when com-
pared to conventional methods. Additionally, we col-
lected data of the leukocytes of participants with cancer.
These findings provided a foundation for future studies
regarding cancer subtype and assay conditions. The
implications of these findings are intended to provide
an early milestone, as we search for ways the SR/CR-
based findings can have therapeutic relevance for
humans.
Methods
Study Design
A modified cytotoxicity assay and the existence of CKA
in the leukocytes of humans were investigated in a ran-
domized case-control pilot study. In addition, the varia-
tion of CKA within three healthy individuals over time
was investigated in an initial set of optimization studies.
Participant Recruitment
Between April of 2006 and July of 2007, 48 study parti-
cipants were recruited among the Wake Forest Univer-
sity Baptist Medical Center Comprehensive Cancer
Center as cancer patients or otherwise healthy indivi-
duals. All participants were entered into the study under
approval and guidance obtained from the Wake Forest
University Institutional Review Board. Participant selec-
tion criteria for controls included individuals with: 1) no
serious medical or psychiatric condition that would pro-
hibit consent and sample collection, 2) no personal his-
tory of cancer, and 3) no history of immunosuppressive
therapy or radiation therapy for any disease. Participant
selection criteria for cases included individuals with: 1)
no serious medical or psychiatric condition that would
prohibit consent or sample collection, 2) a diagnosis of
metastatic cancer, and 3) no history of chemotherapy or
radiation therapy within three months prior to the sam-
pling date. In addition to health status, demographic
information of participants including age, gender, and
ethnicity was collected.
Sample Procurement and Processing
From each participant, 24-30 mL of blood was collected
by venipuncture into three Vacutainer
® CPT
® Cell Pre-
paration Tubes with Sodium Citrate (Becton, Dickinson
and Company, Franklin Lakes, NJ). Samples were
labeled with a coded study number by a clinical coordi-
nator, and transported immediately to an on-site proces-
sing facility. Upon receipt, coded samples were
processed according to the manufacture’s instructions,
thereby producing a fraction of mononuclear (MNC)
leukocytes from each sample. Viable leukocytes were
quantified with a haemocytometer based on ability to
exclude trypan blue dye.
Cancer Target Maintenance
The HeLa cell line, which originated from human cervi-
cal adenocarcinoma, was chosen as the target for use in
the assay (American Type Tissue Culture Collection,
Manassas, VA). HeLa cells were maintained using stan-
dard tissue culture methods. Briefly, HeLa cells were
grown and maintained at 37°C, 8% CO2, in T75 cm
2 cell
culture flasks in Dulbecco’s Modified Eagle’sM e d i u m
(D-MEM) (Invitrogen, Carlsbad, CA) supplemented with
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Bovine Serum (FBS) (Sigma. St. Louis, MO), Penicillin
(Sigma. St. Louis, MO), Streptomycin (Sigma. St. Louis,
MO) & supplemental L-glutamine (Sigma. St. Louis,
MO). HeLa cell culture were split and passaged before
reaching 70% surface confluence in culture flasks.
Leukocyte-mediated Cancer Killing Activity (CKA) Assay
CKA was determined through the use of a modified
form of the SR/CR in vitro cytotoxicity assay, published
previously [5,11]. Incubation times were either 12 hr or
24 hr, while most presented data came from 24 hr incu-
bation. The effector to target ratio used in these studies
ranged between 19 to 28 effectors per target. These con-
ditions were emulated from the mouse-specific CKA
assay, while items including tumor target selection and
effector sample collection were altered in order to adapt
the assay for use in humans. Briefly, isolated leukocytes
were co-incubated in BD Falcon 35 mm
2 cell culture
dishes (Becton-Dickinson, Franklin Lakes, NJ) with
adherent HeLa tumor targets at desired effector to tar-
get ratios. HeLa targets were allowed to reach approxi-
mately 60-80% confluence at 37°C prior to effector
addition. Following effector addition, all assays including
controls were carried out at 39°C. Each data point
represented duplicates or triplicates of the same assay.
In parallel wells, duplicate HeLa cells were incubated
alone without effector cells as controls. Following incu-
bation, samples were washed twice with Phosphate Buf-
fered Saline (PBS) to remove leukocytes and dead or
dying target cells that were detached from culture sur-
faces. Remaining live adherent target cells were treated
with PBS containing 0.25% trypsin and 0.05% EDTA.
Trypsinization was halted with the addition of culture
media containing 10% fetal bovine serum. Samples were
centrifuged at 400 × g for 5 min and resuspended in
ice-cold PBS. Trypan-blue-excluding cells were quanti-
fied with a haemocytometer.
Statistical Analyses
CKA was defined as the arithmetic difference in the
number of trypan-blue-negative cells in the control
group from the number of trypan-blue-negative cells in
the experimental group, expressed as a percentage of
the number of trypan blue negative cells in the control
group:
Student’s t-test (for Total), c
2 tests, and two way
ANOVA were used to compare control and case demo-
graphic variables. Binary logistic regression was used to
calculate odds ratios (OR) and 95% confidence intervals
(CI) for the association between CKA activity and can-
cer risk. Statistical analyses were completed using SPSS
v. 17.0 (SPSS, Chicago, IL).
Results
Cancer Killing Activity and Participant Demographics
Table 1 summarizes the demographic characteristics of
cases and controls. The mean and standard deviation of
CKA are also presented. There were no significant dif-
ferences in the distribution of controls and cases by gen-
der, ethnicity, or age. Overall, CKA was higher in
controls (mean = 46.28; SD = 27.22) compared to cases
(mean = 36.97; SD = 21.39), although the results did not
reach statistical significance (p = 0.20). Males had signif-
icantly higher CKA compared to females (ANOVA, p =
0.001). This relationship was apparent among both cases
and controls, and subsequently investigated in an asso-
ciation study of cancer risk (see Table 2). There was no
significant difference in CKA by ethnicity or age.
Association of Cancer Killing Activity and Cancer Risk
The association between CKA and cancer risk is shown
in Table 2. The cutoff value (50.0) is based on the med-
ian value of the control group to divide subjects into
dichotomous groups. (A) Females with low CKA had a
higher cancer risk (OR = 3.85, 95% CI = 0.64, 23.05),
although these results did not approach significance. (B)
Males with low CKA had nearly a four fold but not sig-
nificant increase in cancer risk (OR = 3.75, 95% CI =
0.47, 29.75). The small subgroup sample size could be a
contributing factor for these results not approaching sig-
nificance. (C) Total population with low CKA had a sig-
nificant increased cancer risk (OR = 4.36, 95% CI =
1.06, 17.88) after adjusting for gender and age.
Table 1 Cancer Killing Activity (CKA) in Controls and
Cases by Gender, Race, and Age
Variable Controls Cases Chi-Square
p
ANOVA
p
N
(%)
Mean
(SD)
N
(%)
Mean
(SD)
Total 25
(53)
46.28
(27.22)
22
(47)
36.97
(21.39)
0.20
Gender
Female 17
(68)
37.20
(23.85)
13
(59)
28.83
(16.15)
Male 8 (32) 65.57
(24.76)
9 (41) 48.72
(23.39)
0.61 0.001
Race
White 24
(96)
47.73
(26.79)
20
(95)
36.11
(21.53)
Black 1 (4) 11.42 1 (5) 54.95 0.93 0.62
Age
<6 0 1 4
(56)
38.43
(24.30)
8 (36) 34.06
(15.18)
≥ 60 11
(44)
56.28
(28.53)
14
(64)
38.63
(24.63)
0.18 0.13
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Time
Figure 2 provides a summary of a preliminary investiga-
tion regarding the variation of CKA among three
healthy individuals, over time.
Discussion and Conclusions
Overall, these results suggest that human leukocytes
possess varying levels of CKA. Additionally, several intri-
guing findings were obtained from our initial compari-
son of CKA among healthy participants or those with
cancer. The results of an association study between can-
cer risk and CKA presented significant findings when
adjusting for an observed gender bias (Table 2). Specifi-
cally, these findings suggested that participants with
cancer were 4.36 times more likely to possess effector
leukocytes that displayed a CKA below 50% against
HeLa cancer targets, in vitro. Also, although not signifi-
cantly different, the sample mean CKA value among
cases was lower than that of controls. The result of this
comparison was also displayed within demographic sub-
groups of gender and age (Table 1). Given the range of
CKA values collected, these levels appear to be compar-
able to historical CKA levels of greater than 50% among
SR/CR mouse leukocytes (Figures 1A and 1B) [5]. More-
over, these results suggest that components of cancer
resistance, such as enhanced immune function witnessed
i nS R / C Rm i c e ,m a ya l s ob ed e t e c t a b l et h r o u g ht h eu s e
of a similar human in vitro assay described here.
Upon review of these findings, several considerations
m a ya i di nt h ef u t u r ed e v e l o p m e n to ft h ein vitro cyto-
toxicity assay for humans. One such condition is appar-
ent upon inspection of the distribution of CKA among
cases versus controls. As illustrated in Figure 1B, the
majority of CKA values among cases are less than 50%,
whereas CKA values measured from controls display lar-
ger variation. Generally, controls presented CKA values
that were either high or low, whereas cases more com-
monly presented low CKA values. This relationship is
affirmed by a consistent finding among SR/CR mice in
regards to the in vitro cytotoxicity assay. As previously
reported in 2006, Hicks et al. demonstrated that the use
of the in vitro cytotoxicity assay could serve as a predic-
tive indicator for the SR/CR phenotype among naïve
pups [11]. These results showed that 84% of mice with
CKA values greater than 50% were later found to be
Table 2 Association Between CKA Activity and Cancer
Risk
Gender Controls
N (%)
Cases
N (%)
OR (95% CI) Adj. OR (95% CI)
2
(A) Females
≥ 50.0
1 7 (41) 2 (15)
< 50.0 10 (59) 11 (85) 3.85 (0.64, 23.05)
(B) Males
≥ 50.0 6 (75) 4 (44)
< 50.0 2 (25) 5 (56) 3.75 (0.47, 29.75)
(C) Total
≥ 50.0 13 (52) 6 (29)
< 50.0 12 (48) 15 (71) 2.89 (0.85, 9.82) 4.36 (1.06, 17.88)
1 The cutoff value based on the median CKA activities of all controls
2 OR adjusted for gender and age (≥ 50, < 50)
Figure 1 Distribution of CKA among subgroups. Figure 1 shows a box plot representing the CKA of seven groups. The top and bottom
portions of the boxes represent the 75
th and 25
th percentiles, whereas the lines in the middle of the boxes represent the median or 50
th
percentile of the CKA distribution. The whiskers represent the upper and lower adjacent values. A) Subject groups are defined as: female cases
(median = 24.5), male cases (median = 46.5), female controls (median = 38.4), and male controls (median = 72.7). B) Summary distribution of
CKA values from all cases (median = 35.0) and controls (median = 50.0) as well as CKA measures obtained from thioglycollate-elicited peritoneal
infiltrating leukocytes of SR/CR mice against S180 tumor targets (median 59.2).
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with CKA values less than 50% were later found to die
from the same cancer challenge. These findings suggest
that measured values of in vitro CKA are consistently
low in susceptible mice. When these historical findings
in SR/CR mice are combined with observations from
the human results in this study, an intriguing pattern
arises regarding the accuracy of the in vitro cytotoxic
assay. Since an otherwise healthy individual could pos-
sess low immunological function, the possibility arises
that CKA may be a dynamic value among individuals
and possibly more sensitive than we originally antici-
pated. The evaluation of conditions that affect the stabi-
lity and sensitivity of this assay is an ongoing subject of
our investigation, specifically by consistently measuring
CKA in the same individual over an extended time
frame. Figures 2A and 2B demonstrate early results of
our ongoing preliminary investigation, in which we
repeatedly sampled the same healthy individuals. Results
of these studies indicate that CKA is persistent among
individuals, and warrants future investigation in order to
generate a CKA baseline for each individual. Eventually
such a measurement may be capable of reflecting the
transient nature of the immunological anti-cancer capa-
city within a healthy individual. The changes in CKA
could coincide with transient influencing factors, such
as stress, or otherwise unforeseen immunological sup-
pression due to infection or disease [14-18]. Pending
future studies, the use of CKA may serve as a functional
marker for immunological status thereby serving as a
risk factor for diseases that are dependant on immuno-
logical function, such as infection and cancer.
Given the relatively small study size, we suspect that
the heterogeneity of CKA among specific cancer sub-
types may also contribute to the statistically insignificant
difference between total sample means (Table 1 and Fig-
ure 1B). Eligibility criteria within the context of this
study required patients to have metastatic disease and
did not limit inclusion to one specific type of cancer
diagnosis. An ad hoc analysis of patient diagnosis did
not reveal a clear trend among individuals, as most can-
cer origin subtypes were only represented once among
cases. In response to this dilemma, we intend to expand
the cancer targets being assessed for CKA per patient.
Ideally, cancer targets that are more appropriately repre-
sentative of the disease subtype of an individual would
more accurately reflect the immune system’sc o n t r i b u -
tion to the individual’s disease as determined by the in
vitro assay. Additionally, results of such panels may
eventually help to identify potential leukocyte effector
subsets that have a more profound effect on specific
cancer types. It is of great interest to investigate CKA
among multiple leukocyte subtypes in order to deter-
mine their independent effects as well as to identify the
optimal effector population subsets that could be tar-
geted for therapeutic use in the future. Current efforts
are underway by our laboratory to develop the in vitro
cytotoxicity assay for use in a high-throughput technol-
ogy. Such technology would increase experimental effi-
ciencies, which would help in addressing conditional
Figure 2 Sample Variation and Presence of CKA over time. Figure 2 represents the results of repeated measures of CKA over time in each of
three healthy individuals. A) Mean CKA values, along with standard deviations were collected, analyzed and summarized by day of collection,
per individual. B) A summary of these values is presented as the distribution of CKA among each individual. Horizontal bars indicate mean CKA
values, along with standard deviation per individual.
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answering these many developing questions.
Patient demographics were also sampled in this study,
illustrating that gender alone demonstrated a significant
difference in CKA among both cases and controls
(Table 1). This observation led to an association-adjust-
ment due to gender and age bias between cancer risk
and CKA (Table 2). A clear reasoning as to why gender
would display this affect on CKA remains unknown, yet
gender-specific trends regarding cancer incidence are
reported and well established [19,20]. This result is in
agreement with the cytotoxic measures witnessed by
Imai et al., showing that among all individuals across all
age groups, cytotoxicity was detected at higher levels in
leukocytes from men rather than in women [7]. An
obvious difference in women that could possibly explain
the modulation of immune responses is the presence of
elevated estrogen levels relative to men [21]. Estrogen
has been shown to suppress NK-mediated cytotoxicity
in a dose dependent manner [22]. Also, estrogen effects
on macrophages have been shown to reduce TNFa
expression, due to the inhibition of transcription factors
by the estrogen-ER complex [23]. Future correlative
investigations regarding the level of estrogen or other
gender-specific hormones may be of value to discern
why women have lower levels of CKA.
Age, when divided into two groups: a) greater than, or
b) less than 60 years of age, showed no significant differ-
ences among both cases and controls (Table 1). This
finding suggests that age did not show differences in
CKA observed among cases and controls. This was an
anticipated finding given that cases were matched with
s i m i l a r l ya g e dc o n t r o l sw h e np o s s i b l eb yt h ec l i n i c a l
coordinator. Future studies that specifically target age as
a discerning factor would be of value given the relation-
ship in humans between cancer incidence, mortality and
age [5,11-13,24-27]. Results regarding ethnicity remain
inconclusive in this study, as sufficient representative
sampling did not occur. In the future, it will be a crucial
requirement to our understanding of CKA to study eth-
nicity-based values in humans, as incidences of some
forms of cancer are known to occur in disparity between
specific populations [20,28,29].
In order to translate the anti-cancer therapeutic effect,
which has previously been demonstrated by SR/CR leu-
kocyte adoptive transfers in mice [11], it is imperative
that we identify biological markers of this unique phe-
notype in humans. The existence of CKA in humans, as
we have demonstrated here, is an initial step towards
that goal.
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